Trial Profile

A Phase I, randomized, double-blind, placebo-controlled, multiple-dose platform study investigating the immunopharmacology of EDP1815 and EDP2939

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EDP 2939 (Primary) ; EDP-1815 (Primary)
Indications Atopic dermatitis; COVID 2019 infections; Inflammation; Psoriasis
Focus Pharmacodynamics
Sponsors Evelo Biosciences

Most Recent Events

18 May 2023 Status changed from recruiting to completed.
20 Feb 2023 According to ISRCTN: Current Controlled Trials, overall trial end date is 30 Sep 2023.
05 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com